Abbott Laboratories (ABT)vsInogen Inc (INGN)
ABT
Abbott Laboratories
$101.95
-1.36%
HEALTHCARE · Cap: $176.41B
INGN
Inogen Inc
$5.31
+2.51%
HEALTHCARE · Cap: $143.04M
Smart Verdict
WallStSmart Research — data-driven comparison
Abbott Laboratories generates 13048% more annual revenue ($46.59B vs $354.30M). ABT leads profitability with a 11.7% profit margin vs -6.9%. ABT appears more attractively valued with a PEG of 1.90. ABT earns a higher WallStSmart Score of 54/100 (C-).
ABT
Buy54
out of 100
Grade: C-
INGN
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-37.5%
Fair Value
$74.13
Current Price
$101.95
$27.82 premium
Margin of Safety
+88.9%
Fair Value
$55.09
Current Price
$5.31
$49.78 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Generating 2.1B in free cash flow
Reasonable price relative to book value
Earnings expanding 87.3% YoY
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Premium valuation, high expectations priced in
Earnings declined 47.5%
3.0% revenue growth
Distress zone — elevated risk
Smaller company, higher risk/reward
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : ABT
The strongest argument for ABT centers on Market Cap, Free Cash Flow. Revenue growth of 13.0% demonstrates continued momentum.
Bull Case : INGN
The strongest argument for INGN centers on Price/Book, EPS Growth, Debt/Equity.
Bear Case : ABT
The primary concerns for ABT are PEG Ratio, P/E Ratio, EPS Growth.
Bear Case : INGN
The primary concerns for INGN are Revenue Growth, Altman Z-Score, Market Cap.
Key Dynamics to Monitor
ABT profiles as a value stock while INGN is a turnaround play — different risk/reward profiles.
INGN carries more volatility with a beta of 1.60 — expect wider price swings.
ABT is growing revenue faster at 13.0% — sustainability is the question.
ABT generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
ABT scores higher overall (54/100 vs 49/100) and 13.0% revenue growth. INGN offers better value entry with a 88.9% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Abbott Laboratories
HEALTHCARE · MEDICAL DEVICES · USA
Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.
Visit Website →Inogen Inc
HEALTHCARE · MEDICAL DEVICES · USA
Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other physicians, and third-party payers in the United States and internationally. The company is headquartered in Goleta, California.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?